Others here see fair value at .33 per share minumum, despite the dilution that took place. A/S @ 200mn is almost maxed out from the latest 191mn shares O/S. Some warrants still left but Roth Capital Partners has been hired to restructure. My guess is they want the share price back up to $1 to meet NASDAQ requirements.
A couple of FDA approvals are expected by year end and they have a good pipeline. Stock way oversold...see RSI and other technicals. Generating more and more revenue and waiting on 3Q15 results.